OSLO, Norway, June 6, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that its Chief Scientific Officer, Jostein Dahle, will present results from preclinical studies with 212PB-NNV003, a novel Targeted Alpha Therapy comprising its proprietary CD37-specific antibody (NNV003) coupled with the alpha-particle generating radioisotope
The presentation will take place at 13th June 09:30-10:00 CEST and is entitled:
Targeted alpha therapy with 212Pb-NNV003 for the treatment of CD37 positive B-cell chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL)
CD37 is highly and selectively expressed on the surface of mature B lymphocytes and B-cell malignancies and may become a useful alternative to the CD20 target, due to the emergence of resistance to anti-CD20 therapies.
Alpha-emitting radionuclides have demonstrated good potential for cancer targeted therapies because of short-range alpha energy deposition (50–100 µm) that causes irreparable DNA double-strand breaks and localized cytotoxicity while sparing surrounding healthy tissues.
The targeted alpha therapy 212Pb-NNV003 has been developed under a collaboration between Nordic Nanovector and Orano Med.
For further information, please contact:IR enquiries Malene BrondbergVP Investor Relations and Corporate CommunicationsCell: +44-7561-431-762Email: email@example.com
International Media Enquiries Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44-207-638-9571Email: firstname.lastname@example.org
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
Further information can be found at www.nordicnanovector.com
This press release contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-to-present-preclinical-studies-with-212pb-nnv003-a-novel-cd37-specific-targeted-alpha-therapy-for-cll-and-nhl-at-trp-2019-300863130.html
SOURCE Nordic Nanovector
Subscribe to our Free Newsletters!